Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Lili Du(The University of Texas MD Anderson Cancer Center), Christina Yau(University of California, San Francisco), Lamorna Brown Swigart(University of California, San Francisco), Rebekah Gould(The University of Texas MD Anderson Cancer Center), Gregor Krings(University of California, San Francisco), Gillian L. Hirst(University of California, San Francisco), Isabelle Bedrosian(The University of Texas MD Anderson Cancer Center), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Jodi M. Carter(Mayo Clinic), Martin Klein(University of Minnesota), Sara J. Venters(University of California, San Francisco), Sonal Shad(University of California, San Francisco), Marieke van der Noordaa(University of California, San Francisco), A. Jo Chien(University of California, San Francisco), Tufia C. Haddad(Mayo Clinic), Claudine Isaacs(Georgetown University), Lajos Pusztai(Yale University), Kathy S. Albain(Loyola University Chicago), Rita Nanda(University of Chicago), Debu Tripathy(The University of Texas MD Anderson Cancer Center), M.C. Liu(Mayo Clinic), Judy C. Boughey(Mayo Clinic), Richard B. Schwab(University of California San Diego), Nola M. Hylton(University of California, San Francisco), Angela DeMichele(University of Pennsylvania), Jane Perlmutter(Gemini Computers (United States)), Douglas Yee(University of Minnesota), Donald A. Berry(The University of Texas MD Anderson Cancer Center), Laura van’t Veer(University of California, San Francisco), Vicente Valero(The University of Texas MD Anderson Cancer Center), Laura J. Esserman(University of California, San Francisco), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)
Cited by 45Open Access
Abstract
Related Papers
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
W. Fraser Symmans, Florentia Peintinger, Christos Hatzis et al.|Journal of Clinical Oncology|2007|1.7k
Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
Clifford A. Hudis, William E. Barlow, Joseph P. Costantino et al.|Journal of Clinical Oncology|2007|885